Inflammatory proteins in diabetic kidney disease-potential as biomarkers and therapeutic targets

Angie S Xiang¹, Elif I Ekinci^{2

3}, Richard J MacIsaac^{3

4}

Affiliations

¹ Central Clinical School, Monash University, Victoria, Australia.
² Endocrine Center, Austin Health, Melbourne, Victoria, Australia.
³ Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
⁴ Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Victoria, Australia.

Editorial

Angie S Xiang et al. Ann Transl Med. 2019 Sep.

. 2019 Sep;7(Suppl 6):S243.

doi: 10.21037/atm.2019.08.20.

Angie S Xiang¹, Elif I Ekinci^{2

3}, Richard J MacIsaac^{3

4}

¹ Central Clinical School, Monash University, Victoria, Australia.
² Endocrine Center, Austin Health, Melbourne, Victoria, Australia.
³ Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
⁴ Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Victoria, Australia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.
Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS. Niewczas MA, et al. Nat Med. 2019 May;25(5):805-813. doi: 10.1038/s41591-019-0415-5. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011203 Free PMC article.

1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol 2017;12:2032-45. 10.2215/CJN.11491116 - DOI - PMC - PubMed
1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211-59. 10.1016/S0140-6736(17)32154-2 - DOI - PMC - PubMed
1. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 2014;63:S39-62. 10.1053/j.ajkd.2013.10.048 - DOI - PubMed
1. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 2014;37:867-75. 10.2337/dc13-1870 - DOI - PubMed
1. MacIsaac RJ, Ekinci EI, Jerums G. Progressive diabetic nephropathy. How useful is microalbuminuria?: contra. Kidney Int 2014;86:50-7. 10.1038/ki.2014.98 - DOI - PubMed